Marinus Pharmaceuticals Inc (NASDAQ:MRNS) CEO Christopher Michael Cashman sold 9,566 shares of Marinus Pharmaceuticals stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $6.28, for a total transaction of $60,074.48. Following the sale, the chief executive officer now owns 247,903 shares of the company’s stock, valued at $1,556,830.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) opened at $5.85 on Wednesday. The company has a market cap of $236.52, a price-to-earnings ratio of -6.29 and a beta of 2.09. Marinus Pharmaceuticals Inc has a 1-year low of $1.13 and a 1-year high of $9.87.
A number of research analysts recently issued reports on MRNS shares. ValuEngine downgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. BidaskClub downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, Laidlaw started coverage on shares of Marinus Pharmaceuticals in a research report on Thursday, December 14th. They set a “buy” rating and a $18.00 price objective for the company.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jennison Associates LLC increased its stake in Marinus Pharmaceuticals by 67.8% in the 4th quarter. Jennison Associates LLC now owns 2,696,553 shares of the biopharmaceutical company’s stock valued at $22,004,000 after buying an additional 1,089,820 shares during the period. Granite Point Capital Management L.P. increased its stake in Marinus Pharmaceuticals by 250.3% in the 3rd quarter. Granite Point Capital Management L.P. now owns 2,684,848 shares of the biopharmaceutical company’s stock valued at $15,760,000 after buying an additional 1,918,400 shares during the period. Perceptive Advisors LLC acquired a new position in Marinus Pharmaceuticals in the 3rd quarter valued at $8,527,000. Citadel Advisors LLC increased its stake in Marinus Pharmaceuticals by 1,889.2% in the 4th quarter. Citadel Advisors LLC now owns 1,022,113 shares of the biopharmaceutical company’s stock valued at $8,340,000 after buying an additional 970,730 shares during the period. Finally, Ascend Capital LLC acquired a new position in Marinus Pharmaceuticals in the 4th quarter valued at $8,264,000. 52.58% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/14/christopher-michael-cashman-sells-9566-shares-of-marinus-pharmaceuticals-inc-mrns-stock.html.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.